GWWSell
W. W. Grainger
Price (1y)
Fair price check
6 different valuation methods each estimate what GWW should be worth, then we compare to today's price.
- EV/EBITDAOvervaluedthinks it's expensive — estimates $1078.83, about 15% below today
- P/E multiplesOvervaluedthinks it's expensive — estimates $1063.78, about 16% below today
- Residual IncomeOvervaluedthinks it's expensive — estimates $373.24, about 71% below today
- DCF (2-stage)Overvaluedthinks it's expensive — estimates $328.05, about 74% below today
- P/B multiplesOvervaluedthinks it's expensive — estimates $287.86, about 77% below today
- Graham (defensive)Outlierestimate looks unreliable — estimates $240.65 — likely unreliable
How to read this: “Cheap” = method's fair price is at least 20% above today. “Fair” = within ±10–20%. “Pricey” = at least 10% below today. Outliers (values more than 5× or less than 0.2× today's price) are excluded.
Fair price ensemble
| Method | Value |
|---|---|
| Graham (defensive) | $240.65 |
| P/E multiples(vs sub industry peers) | $1063.78 |
| P/B multiples(vs sub industry peers) | $287.86 |
| EV/EBITDA(vs sub industry peers) | $1078.83 |
| Residual Income | $373.24 |
| DCF (2-stage) | $328.05 |
- extreme graham estimate
Median of all applicable methods (current price $1272.47). Outliers above 5× or below 0.2× current price are excluded from the max but kept in the median. See methodology for the 6-method ensemble + 7 defenses.
Pillar breakdown
8 dimensions, each scored 0–100 against the universe
- QualityProfit margins & asset efficiency92Strong
- ValuePrice vs fundamentals30Poor
- GrowthRevenue & earnings trajectory56Decent
- MomentumRecent price strength72Strong
- HealthBalance sheet & solvency70Decent
- ProfitabilityROE, ROA, ROIC73Strong
- TechnicalTrend & volatility signals61Decent
- RiskVolatility & drawdown profile67Decent
Pillars not shown: Sentiment, ML (Phase 5+).
Raw fundamentals (SEC EDGAR)
| Metric | Value |
|---|---|
| Market cap | $60.08B |
| Revenue (TTM) | $18.38B |
| Net income (TTM) | $1.89B |
| Operating cash flow (TTM) | $2.11B |
| CapEx (TTM) | $729.00M |
| Free cash flow (TTM)CFO − CapEx | $1.38B |
| Total assets | $9.47B |
| Total liabilities | N/A |
| Stockholders' equity | $3.93B |
| Cash & equivalents | $695.00M |
| Shares outstanding | 47.21M |
| EPS (basic) | $11.67 |
| EPS (diluted) | $11.65 |
| P/E ratio (TTM) | 31.80 |
TTM = trailing twelve months. Balance sheet items are point-in-time (latest filing).
Data quality
- Latest filed date
- 2026-05-07
- Latest period end
- 2026-04-30
- Filing lag
- 9 days
- Missing metrics
- 4(total_liabilities, research_and_development, interest_expense, accounts_payable)
Phase 3c — composite is the 8-pillar weighted score over quality, value, growth, momentum, health, profitability, technical, and risk. Sentiment + ML pillars land in Phases 5-6; until then their weight redistributes pro-rata. Fair price is the median of 6 valuation methods (Graham, P/E / P/B / EV-EBITDA multiples, RIM, DCF) with outliers above 5× current price excluded from the max. Risk-overlay flags annotate only — they suppress the entered-top-5 badge but do not modify the composite.